ALK and non-small cell lung carcinoma: Currently, there are five ALK-TKIs for the treatment of ALK-positive NSCLC, namely crizotinib (1st generation), alectinib, ceritinib, brigatinib (2nd generation), and lorlatinib (3rd generation).